Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease

被引:20
作者
Sethi, S. [1 ,2 ]
Anzueto, A. [3 ]
Miravitlles, M. [4 ]
Arvis, P. [5 ]
Alder, J. [6 ]
Haverstock, D. [6 ]
Trajanovic, M. [7 ]
Wilson, R. [8 ]
机构
[1] SUNY Buffalo, Div Pulm Crit Care & Sleep Med, Buffalo, NY 14260 USA
[2] VA Med Res, 151,3495 Bailey Ave, Buffalo, NY 14215 USA
[3] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA
[4] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain
[5] Bayer HealthCare, Loos, France
[6] Bayer HealthCare Pharmaceut, Whippany, NJ USA
[7] Bayer Inc, Toronto, ON, Canada
[8] Royal Brompton Hosp, Host Def Unit, London SW3 6LY, England
关键词
Bacteriological outcomes; Beta-lactams; Exacerbation of chronic obstructive pulmonary disease; Fluoroquinolones; Risk factors; Systemic corticosteroids; HAEMOPHILUS-INFLUENZAE; BRONCHIAL INFLAMMATION; GENE-EXPRESSION; COPD; MOXIFLOXACIN; ANTIBIOTICS; INFECTIONS; COLONIZATION; PATHOGENESIS; MACROPHAGES;
D O I
10.1007/s15010-015-0833-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Changes in sputum microbiology following antibiotic treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), including patterns of bacteriological relapse and superinfection are not well understood. Sputum microbiology at exacerbation is not routinely performed, but pathogen presence and species are determinants of outcomes. Therefore, we determined whether baseline clinical factors could predict the presence of bacterial pathogens at exacerbation. Bacterial eradication at end of treatment (EOT) is associated with clinical resolution of exacerbation. We determined the clinical, microbiological and therapeutic factors that were associated with bacteriological eradication in AECOPD at EOT and in the following 8 weeks. Sputum bacteriological outcomes (i.e., eradication, persistence, superinfection, reinfection) from AECOPD patients (N = 1352) who were randomized to receive moxifloxacin or amoxicillin/clavulanate in the MAESTRAL study were compared. Independent predictors of bacterial presence in sputum at exacerbation and determinants for bacteriological eradication were analyzed by logistic regression and receiver operating characteristic (ROC) analyses. Significantly greater bacteriological eradication with moxifloxacin was mainly driven by superior Haemophilus influenzae eradication (P = 0.002, EOT). Baseline clinical factors were a weak predictor of the presence of pathogens in sputum (AUC(ROC) = 0.593). On multivariate analysis, poorer bacterial eradication was associated with antibiotic resistance (P = 0.0001), systemic steroid use (P = 0.0024) and presence of P. aeruginosa (P = 0.0282). Since clinical prediction of bacterial presence in sputum at AECOPD is poor, sputum microbiological analysis should be considered for guiding antibiotic therapy in moderate-to-severe AECOPD, particularly in those who received concomitant systemic corticosteroids or are at risk for infection with antibiotic-resistant bacteria.
引用
收藏
页码:65 / 76
页数:12
相关论文
共 36 条
  • [1] Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of COPD
    Adams, SG
    Melo, J
    Luther, M
    Anzueto, A
    [J]. CHEST, 2000, 117 (05) : 1345 - 1352
  • [2] Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease A Randomized Placebo-Controlled Trial
    Bafadhel, Mona
    McKenna, Susan
    Terry, Sarah
    Mistry, Vijay
    Pancholi, Mitesh
    Venge, Per
    Lomas, David A.
    Barer, Michael R.
    Johnston, Sebastian L.
    Pavord, Ian D.
    Brightling, Christopher E.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2012, 186 (01) : 48 - 55
  • [3] Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations
    Berenson, Charles S.
    Kruzel, Ragina L.
    Eberhardt, Ellana
    Dolnick, Ree
    Minderman, Hans
    Wallace, Paul K.
    Sethi, Sanjay
    [J]. THORAX, 2014, 69 (09) : 811 - 818
  • [4] Phagocytic Dysfunction of Human Alveolar Macrophages and Severity of Chronic Obstructive Pulmonary Disease
    Berenson, Charles S.
    Kruzel, Ragina L.
    Eberhardt, Ellana
    Sethi, Sanjay
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (12) : 2036 - 2045
  • [5] Microbiome Diversity in the Bronchial Tracts of Patients with Chronic Obstructive Pulmonary Disease
    Cabrera-Rubio, Raul
    Garcia-Nunez, Marian
    Seto, Laia
    Anto, Josep M.
    Moya, Andres
    Monso, Eduard
    Mira, Alex
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (11) : 3562 - 3568
  • [6] Clinical Laboratory Standards Institute, 2009, MA07A8 CLSI
  • [7] Antibiotics in Addition to Systemic Corticosteroids for Acute Exacerbations of Chronic Obstructive Pulmonary Disease
    Daniels, Johannes M. A.
    Snijders, Dominic
    de Graaff, Casper S.
    Vlaspolder, Fer
    Jansen, Henk M.
    Boersma, Wim G.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181 (02) : 150 - 157
  • [8] Changes in prevalence and load of airway bacteria using quantitative PCR in stable and exacerbated COPD
    Garcha, Davinder S.
    Thurston, Sarah J.
    Patel, Anant R. C.
    Mackay, Alexander J.
    Goldring, James J. P.
    Donaldson, Gavin C.
    McHugh, Timothy D.
    Wedzicha, Jadwiga A.
    [J]. THORAX, 2012, 67 (12) : 1075 - 1080
  • [9] Changes in bronchial inflammation during acute exacerbations of chronic bronchitis
    Gompertz, S
    O'Brien, C
    Bayley, DL
    Hill, SL
    Stockley, RA
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2001, 17 (06) : 1112 - 1119
  • [10] Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae
    Kratzer, Christina
    Graninger, Wolfgang
    Macfelda, Karin
    Buxbaum, Astrid
    Georgopoulos, Apostolos
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2007, 119 (9-10) : 297 - 302